Semaglutide dosing on the Wegovy® label, 0.25mg to 2.4mg, and who sets a compounded semaglutide dose

What is the semaglutide dosing schedule on the FDA-approved Wegovy® label?

The FDA-approved Wegovy® (semaglutide) prescribing information from Novo Nordisk, revised June 2026, sets out the injection schedule below. These are brand-label facts. The Wegovy® label allows the prescribing provider to delay an escalation step for 4 weeks if a dose is not tolerated and to choose the maintenance dose by indication. Compounded semaglutide is not FDA-approved and has no FDA-approved dosing label; the prescribing provider sets each patient's dose.

The Wegovy® label specifies injection once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm.

What are the semaglutide maintenance doses on the Wegovy® label?

The FDA-approved Wegovy® (semaglutide) label lists maintenance doses for injection by indication:

• Weight reduction in adults: 1.7 mg or 2.4 mg (recommended) once weekly. For adults who tolerate 2.4 mg for at least 4 weeks, the label permits an increase to a maximum of 7.2 mg injected subcutaneously once weekly when additional weight reduction is clinically indicated. The 7.2 mg pen is Wegovy® HD.
• Cardiovascular risk reduction in adults: 2.4 mg (recommended) or 1.7 mg once weekly.
• Weight reduction in pediatric patients aged 12 years and older: 2.4 mg (recommended) or 1.7 mg once weekly.
• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults: 2.4 mg once weekly; if that dose is not tolerated, the label allows 1.7 mg and consideration of re-escalation.

The Wegovy® label directs the provider to consider treatment response and tolerability when selecting the maintenance dosage. Compounded semaglutide is not FDA-approved and has no FDA-approved maintenance-dose label; the prescribing provider determines each patient's dose.

How is Ozempic dosing different from Wegovy dosing?

FDA-approved Ozempic® and Wegovy® contain the same molecule, semaglutide, and are made by Novo Nordisk. The Ozempic® label covers three indications in adults with type 2 diabetes: glycemic control; reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. Ozempic® is not approved for weight management.

The Ozempic® label starts at 0.25 mg once weekly and increases to 0.5 mg after 4 weeks. If additional glycemic control is needed, the label permits 1 mg after at least 4 weeks on 0.5 mg, then 2 mg after at least 4 weeks on 1 mg; 2 mg is the maximum weekly dose. For glycemic control, the Ozempic® label's maintenance dose is 0.5 mg, 1 mg or 2 mg once weekly; for adults with type 2 diabetes and chronic kidney disease, it is 1 mg once weekly, started after at least 4 weeks on 0.5 mg. The Ozempic® label says to take a missed dose as soon as possible within 5 days, or to skip it if more than 5 days have passed. For Wegovy® injection, the label says to take a missed dose if the next scheduled dose is more than 2 days away, or skip it if the next dose is less than 2 days away. Compounded semaglutide is not FDA-approved and is not therapeutically equivalent to FDA-approved Wegovy® or Ozempic®.

How are Wegovy® tablets dosed?

The FDA-approved Wegovy® label describes oral semaglutide tablets for cardiovascular risk reduction or weight reduction in adults. Its tablet schedule is 1.5 mg once daily on days 1–30, 4 mg on days 31–60, 9 mg on days 61–90, and 25 mg from day 91 as the recommended maintenance dose. The Wegovy® label says to take the tablet on an empty stomach in the morning with up to 4 ounces of water, swallow it whole, and wait at least 30 minutes before food, drink or other oral medications. The tablet and injection schedules describe separate products with separate labeling instructions. Compounded semaglutide is not FDA-approved and has no FDA-approved dosing label; the prescribing provider sets the dose.

Why does the Wegovy® label start semaglutide at 0.25mg and increase slowly?

The FDA-approved Wegovy® (semaglutide) label states that dose escalation is followed to reduce the risk of gastrointestinal adverse reactions. The injection label starts at 0.25 mg once weekly for 4 weeks and escalates every 4 weeks toward the maintenance dose. If a dose is not tolerated during escalation, the Wegovy® label allows consideration of delaying escalation for 4 weeks.

Contact your prescribing provider promptly for severe or persistent stomach symptoms such as nausea, vomiting, diarrhea or abdominal pain, or if you cannot keep fluids down. The Wegovy® label describes pancreatitis symptoms as severe abdominal pain that sometimes radiates to the back, with or without nausea or vomiting, and instructs patients to discontinue Wegovy® promptly and contact their physician if pancreatitis is suspected. For hypersensitivity reactions, the Wegovy® label instructs patients to discontinue Wegovy® and seek medical advice promptly if symptoms occur. For trouble breathing or swelling of the face, lips, tongue or throat, seek emergency care. Never change your dose without your prescribing provider. The GLP-1 side effects guide provides additional context. Compounded semaglutide is not FDA-approved; the prescribing provider sets the dose and advises on symptoms. The Wegovy® label lists the adverse reactions below as the most common (reported in at least 5% of patients).

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Dysesthesia (abnormal skin sensations)
• Headache
• Fatigue
• Dyspepsia (indigestion)
• Dizziness
• Abdominal distension
• Eructation (burping)
• Hypoglycemia in patients with type 2 diabetes
• Flatulence
• Gastroenteritis
• Gastroesophageal reflux disease
• Hair loss

What is the boxed warning on the Wegovy® and Ozempic® labels?

The FDA-approved Wegovy® and Ozempic® (semaglutide) labels carry a boxed warning for the risk of thyroid C-cell tumors. The Wegovy® and Ozempic® labels state that semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether Wegovy® or Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The Wegovy® and Ozempic® labels contraindicate use in patients with a personal or family history of MTC, in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients who have had a serious hypersensitivity reaction to semaglutide or to any of the product's excipients. The Wegovy® and Ozempic® labels counsel patients on symptoms of thyroid tumors, such as a mass in the neck, trouble swallowing, shortness of breath or persistent hoarseness. Tell your prescribing provider about any personal or family history of thyroid cancer or MEN 2, and about any serious allergic reaction, before starting treatment. Compounded semaglutide is not FDA-approved and has no FDA-approved label; the prescribing provider reviews each patient's history before prescribing.

What do the Wegovy® and Ozempic® labels say about a missed semaglutide dose?

The FDA-approved Wegovy® injection label says to take a missed dose as soon as possible if the next scheduled dose is more than 2 days away. If the next scheduled dose is less than 2 days away, skip the missed dose and resume on the regularly scheduled day. If 2 or more consecutive Wegovy® injection doses are missed, the label directs re-initiation of dose escalation at a lower dose to reduce the risk of gastrointestinal adverse reactions; the prescribing provider decides the restart dose.

The Wegovy® tablet label says to skip a missed tablet dose and take the next dose the following day. The FDA-approved Ozempic® label says to take a missed dose as soon as possible within 5 days after the missed dose; if more than 5 days have passed, skip it and take the next dose on the regularly scheduled day. Compounded semaglutide is not FDA-approved and has no FDA-approved dosing label. For compounded semaglutide, follow the prescribing provider's and dispensing pharmacy's instructions for missed doses; contact them if the directions are unclear.

How is compounded semaglutide dosed compared with Wegovy or Ozempic?

Brand-name and compounded doses are not interchangeable, and there is no dose conversion between them; your provider determines the right dose based on your history. Compounded semaglutide is not FDA-approved and is not therapeutically equivalent to FDA-approved Wegovy® or Ozempic®. Compounded semaglutide prescribed through Cora Health is prepared under patient-specific prescriptions by US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx.

Compounded semaglutide vial concentration (mg/mL) varies by pharmacy, so the same milligram dose can occupy a different injection volume from one vial to another. The dispensing pharmacy's label states the concentration, and the prescribing provider's instructions state the amount to draw. Never use a brand pen's markings or another vial's injection volume for a compounded semaglutide vial. Ask the dispensing pharmacy and prescribing provider to clarify any mismatch before drawing an injection.

How much does compounded semaglutide cost through Cora Health?

On the Cora Health Essential Plan, compounded semaglutide prescribed through Cora Health has four standard billing tiers: annual at $99/month ($1,188 billed upfront every 12 months); semi-annual at $120/month ($720 billed upfront every 6 months); quarterly at $145/month ($435 billed upfront every 3 months); and monthly at $175/month ($175 billed monthly). Plans renew automatically until you cancel. Prices may change. Each price includes the provider consultation, the medication, pharmacy fulfillment, shipping and ongoing provider monitoring, and on the standard plans the price does not change with your dose. A licensed provider decides eligibility and prescribes only when clinically appropriate. Compounded semaglutide is not FDA-approved. More pricing detail is in the semaglutide cost guide; cancellation terms are in the refund policy.

Who prescribes compounded semaglutide through Cora Health?

Cora Health does not prescribe medication. Cora Health connects patients with licensed providers at Wasef Health, PC, who evaluate each patient and prescribe compounded semaglutide only when clinically appropriate. The prescribing provider reviews the patient's history, decides eligibility and sets the patient's dose. A consultation does not guarantee a prescription.

Compounded semaglutide prescribed through Cora Health is prepared under patient-specific prescriptions by US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx. Cora Health does not compound medication. Cora Health is LegitScript-certified. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. FDA does not verify the safety, effectiveness or quality of compounded drugs before marketing. The prescribing provider and dispensing pharmacy answer questions about the prescription and pharmacy label.

Sources

All brand-label dosing facts on this page come from the FDA-approved Wegovy® prescribing information (Novo Nordisk, revised June 2026) and Ozempic® prescribing information (Novo Nordisk, revised May 2026). Compounded semaglutide is not FDA-approved.

• Novo Nordisk — Wegovy® prescribing information, revised June 2026: novo-pi.com/wegovy.pdf
• Novo Nordisk — Ozempic® prescribing information, revised May 2026: novo-pi.com/ozempic.pdf
• FDA — Compounding and the FDA: Questions and Answers: fda.gov
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io